醫藥品·生物科技交易的特許權比率

製藥和生物技術項目的特許權費率是一站式來源，提供數百項資本交易的實際交易資訊（許可技術、特許權費率、許可費、預付款、里程碑等）。

本報告提供了最新合作的詳細信息，披露了製藥、生物技術和診斷領域宣布的特許權使用費率。本報告提供了 692 個合作項目的詳細信息，這些項目披露了 2010 年至 2024 年的特許權使用費率。

本報告概述了公司如何以及為何簽訂合作協議，在化合物或技術商業化時支付特許權使用費。

了解潛在合作夥伴談判的交易條款的靈活性可以幫助您深入了解談判過程，了解條款談判期間的預期結果。許多小型企業希望了解有關付款條件的詳細信息，但真正重要的是付款方式 - 合約文件中隱藏著一些在新聞稿或資料庫中找不到的見解。

本報告提供了自 2010 年以來宣布的 692 項合作夥伴交易的完整列表，這些交易記錄在當前協議交易/合作夥伴關係數據庫中，並且我正在定量披露這些交易的特許權使用費。每筆交易的記錄和特許權使用費揭露均透過交易線上副本（如果有取得）的連結提供，包括本公司及其合作夥伴向美國證券交易委員會提交的實際合約文件。

主要優勢

此報告具有以下優點：

• 忠誠度 了解趨勢（自 2010 年以來） < li >使用實際案例研究對特許權使用費條款進行結構分析
• 查看合作夥伴/許可協議：闡明特許權使用費率
• 基準分析：確定交易的市場價值
• 財務條款：一次性付款、里程碑付款、特許權使用費 < li>交易清單：按公司名稱 (A-Z)、按處理重點領域、按技術類型
• 獲取合約文件：有關交易結構的見解
• 盡職調查：評估合作夥伴公司對擬議合約條款的遵守情況
• 節省數百小時的研究時間

研究範圍

• 本報告旨在為讀者提供有關版稅率趨勢和結構的詳細資訊世界領先的生命科學公司進行的資本交易。

本報告包??括：

• 2010年以來生物製藥行業的特許權使用費趨勢 結構分析
• 披露特許權使用費率的真實許可協議案例研究
• 綜合清單已揭露許可 費率的許可協議數量（自 2010 年以來） 訪問
• 主要許可協議的許可費率和金額（自 2010 年以來）
• 最活躍的許可費率披露（自2010 年以來）

本報告涵蓋交易可獲得資訊的項目/合約按以下順序列出：

• 按公司名稱（A-Z）
• 按交易金額
• 按處理領域
• 技術類型單獨
• 每個交易標題都透過網路連結連結到實際交易記錄的線上版本。
• 此報告提供了對許可協議的可用合約文件的全面存取。

藉由實際合約的分析，可得出以下的評估:

• 授予的確切特許權使用費率是多少？
• 合約實際上授予合作夥伴公司什麼？
• 授予哪些類型的專有權？
• 合約結算結構是怎麼樣的？
• 如何審核銷售和付款？
• 合約期限是多久？
• 合約的主要條款是如何定義的？
• 智慧財產權的處理和所有權如何？
• 誰負責商業化？
• 誰負責開發、供應和製造？ <一i=54>
• 如何管理保密與揭露？
• 如何解決爭議？
• 什麼情況下可以取消合約？
• 如果所有者發生變化會怎樣？
• 已就何種類型的分授權或分包條款達成協議？
• 公司主張哪些樣板條款？
• 哪些樣板條款會根據合作夥伴和交易類型的不同而有所不同？
• 公司對契約法主張哪一個管轄權？

目錄

第1章 簡介

• 什麼是版稅？
• 特許權使用費歷史記錄
• 藥品和生物技術特許權使用費
• 特許權使用費和收益分成
• 調查概述

第2章 醫藥品及生物科技的特許權比率概要

• 特許權使用費趨勢（2010-2024 年）
• 如何計算收入佔有率
• 近期文獻回顧
• 未來特許權使用費率

第3章 醫藥品·生物科技交易的忠誠度(權利金)條款

• 合作協議的結構
• 典型版稅條款的結構
• 版稅條款範例
  • 個案研究(1)
  • 個案研究 (2) < li>個案研究（3）
  • 個案研究（4）

第四章積極揭露特許權使用費費率的公司

• 最積極揭露特許權使用費的公司費率

第 5 章特許權使用費率協議清單

• 探索特許權使用費率並獲得更深入的見解
• 交易清單
• 交易清單：交易特許權使用費率 - 按公司姓名 (A-Z)
• 交易清單：交易中的特許權使用費費率- 按治療領域
• 交易清單：交易中的特許權使用費率 - 按合約簽訂時的開發階段
• 交易清單：按治療領域劃分的特許權使用費率交易 - 按技術類型
• 特許權使用費率參考
• 特許權使用費率交易合約範例 < li>關於 Biopharma Research Ltd
• 當前合作夥伴
• 當前協議
• 當前合作夥伴的最新報告標題

Royalty Rates in Pharmaceutical and Biotechnology Deals is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.

This report provides details of the latest partnering deals which disclose a royalty rate announced in the pharmaceutical, biotechnology and diagnostic sectors. The report provides details of 692 partnering deals disclosing royalty rates from 2010 to 2024.

The report provides an overview of how and why companies enter partnering deals where a royalty is payable upon commercialization of the compound or technology.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of 692 partnering deals announced since 2010 where a quantitative royalty rate has been disclosed, as recorded in the Current Agreements deals and alliances database. Each deal record and royalty disclosure is available in further detail via a link to online copy of the deal including actual contract document, where available, as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of royalty rate trends in pharma and biotech since 2010. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in royalty rates in the pharma and biotech sectors since 2010.

Chapter 3 provides a more detailed insight into the structure of a royalty rate clause and how it fits with the other financial terms of the partnering deal.

Chapter 4 provides an insight into companies active in disclosing royalty rates as well as those deals attracting the highest royalty rates.

Chapter 5 provides comprehensive and detailed access to deals which disclose a royalty rate since 2010 where a contract document is available. Contract documents provide an in-depth insight into the actual deal terms agreed between the parties with respect to the royalty rate.

In addition the report includes a comprehensive deal directory listing of all deals where a royalty rate has been disclosed announced since 2010. Each listing is organized as a directory by company A-Z, stage of development at signing, therapeutic area, and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends in royalty rates in pharma and biotech deal making since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about royalty rates in the pharma and biotech sector.

Key benefits

Royalty Rates in Pharmaceutical and Biotechnology Deals provides the following benefits:

• Understand royalty rate trends since 2010
• Analysis of the structure of royalty clauses with real life case studies
• Browse collaboration and licensing deals which reveal a royalty rate
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Royalty Rates in Pharmaceutical and Biotechnology Deals is intended to provide the reader with an in-depth understanding of the royalty rate trends and structure of deals entered into by leading life science companies worldwide.

Royalty Rates in Pharmaceutical and Biotechnology Deals includes:

• Trends in royalty rates in the biopharma industry since 2010
• Analysis of royalty rate clause structure
• Case studies of real-life licensing deals which disclose royalty rates
• Comprehensive listing of licensing deals which disclose royalty rates since 2010
• Access to licensing contract documents which disclose royalty rates
• The leading licensing deals by royalty rate value since 2010
• Most active royalty rate disclosures since 2010

In Royalty Rates in Pharmaceutical and Biotechnology Deals available deals and contracts are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.
• The Royalty Rates in Pharmaceutical and Biotechnology Deals report provides comprehensive access to available contract documents for licensing deals.

Analyzing actual contract agreements allows assessment of the following:

• What are the precise royalty rates granted?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

• 1.1. What are royalties?
• 1.2. History of royalty rates
• 1.3. Royalties in pharmaceuticals and biotechnology
• 1.4. Royalties versus revenue share
• 1.5. Overview of the report

Chapter 2 - An overview of pharmaceutical and biotechnology royalty rates

• 2.1. Trends in royalty rates 2010 - 2024
• 2.2. How do revenue shares figure?
• 2.3. A review of recent literature
• 2.4. Royalty rates in the future

Chapter 3 - The royalty clause in pharmaceutical and biotechnology deals

• 3.1. Partnering agreement structure
• 3.2. Structure of a typical royalty clause
• 3.3. Example royalty clauses
  • 3.3.1. Case study 1
  • 3.3.2. Case study 2
  • 3.3.3. Case study 3
  • 3.3.4. Case study 4

Chapter 4 - Companies actively disclosing royalty rates

• 4.1. Most active companies in disclosing royalty rates

Chapter 5 - Royalty rate contract directory

• Explore royalty rates within the deal contract document to gain greater insight
• Deal Directory
• Deal Directory - Royalty rates in deals - by company A-Z
• Deal Directory - Royalty rates in deals - by therapy area
• Deal Directory - Royalty rates in deals - by stage of development at signing
• Deal Directory - Royalty rates in deals - by technology type
• Royalty rate references
• Example royalty rate deal contract document
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Trends in pharma and biotech royalty rates, 2010 - 2024
• Figure 2: Components of the partnering deal structure
• Figure 3: Components of the partnering royalty clause
• Figure 4: Most active companies disclosing royalty rate 2010 - 2024
• Figure 5: Licensing agreement for rhAAT - rEVO Biologics, LFB Biotechnologies